ReviewTargeted oncology2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.
Review in Targeted oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.Molecular carcinogenesis · 2020Article
- mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).Frontiers in endocrinology · 2020Review
- The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review.Oncotarget · 2017Article
- Article
- Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.Oncotarget · 2016Article
- Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.Oncotarget · 2016Article
- Article
- Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.Journal of hepatology · 2014Review
- Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.Breast cancer research : BCR · 2014Article
- Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.TheScientificWorldJournal · 2014Review
- Tailoring mTOR-based therapy: molecular evidence and clinical challenges.Pharmacogenomics · 2013Review
- Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model.Blood cancer journal · 2013Article
- Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.Frontiers in oncology · 2013Article
- Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.Targeted oncology · 2012Review
- Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling.Current medicinal chemistry · 2012Review
- Are we ready to move away from nature?: the rapamycin story.Targeted oncology · 2011Article
- Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.Targeted oncology · 2011Review
- The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.Targeted oncology · 2011Review
- Targeting the target of rapamycin (TOR): looking to mother nature.Targeted oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the quest for personalized medicine, only a few biological parameters are routinely used to select patients prior to the initiation of anticancer targeted therapies, including mTOR inhibitors. Identifying biological factors that may predict efficacy or resistance to mTOR inhibitors represents an important challenge since rapalogs may exert antitumor effects through multiple mechanisms of action. Despite the fact that no such a factor is currently available, several molecular patterns are emerging, correlating with sensitivity and/or resistance to rapalogs. While activation of the phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, overexpression of cyclin D1, and functional apoptosis seem to sensitize tumor cells to rapalogs, Bcl2 overexpression or KRAS mutations are reported to be associated with resistance to mTOR inhibitors in several preclinical models. Translational research aimed at validating those parameters in clinical trials is ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.